As the MAPK and PI3K–Akt pathways may positively or negatively regulate mutual activities, the combination of BRAF or MEK inhibitors with a PI3K–Akt inhibitor was proposed to overcome the resistance to MAPK inhibitors in BRAF V600E mutant tumours [7]. The gene discussed is MAP2K7; the disease is neoplasm.